CompletedNot Applicable

DHA Supplementation in Patients With STGD3

United States11 participantsStarted 2007-09-21

Plain-language summary

We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, the purpose of this study is to follow STGD3 patients as they supplement their diets with DHA/EPA.

Who can participate

Age range18 Years – 105 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All Moran Eye Center patients with STGD3 Exclusion Criteria: * All others

What they're measuring

ERG

Timeframe: 1 year

Trial details

NCT IDNCT00420602

SponsorUniversity of Utah

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-12-27

View on ClinicalTrials.gov More Dominantly Inherited Stargardt's Disease (STGD3) trials